Moving from IP to Open Source – Adopting a Policy of Open Innovation to the Gamut of Synthetic Biology

Aug-25-13

Patents have been the norm in the growth and development of bio technology. But the US Supreme Court has ruled out genes patenting.

Corporate policy should be long term in medical, materials, energy and agriculture and incorporate open source bio in their open innovation plans.

1. Upstream - Continue with conventional suppliers, licensors and M&A targets through acquisitions and licensing.

2. Mid stream - Tap into a combination of corporate, academic and open source community of established organizations and younger startups.

3. Downstream - Pre-competitive consortia with startups, industry partner programs and academic research for long term future growth.

Next OI News Story »

[LUXRESEARCHINC.COM]